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1  | INTRODUC TION
Medication adherence—where prescribed medications are taken at 
the right doses and times in the manner specified—has been shown 
to improve health outcomes and reduce health- care costs.1,2 Indeed, 
a recent Cochrane review concluded that “increasing the effec-
tiveness of adherence interventions may have a far greater impact 
on the health of the population than any improvement in specific 
medical treatments.”3 Non- adherence, which can take the form of 
non- initiation and non- persistence, is closely linked with treatment 
efficacy and disease progression,4 as well as inappropriate up- 
titration, with subsequent risk of interactions and adverse drug re-
actions.5 Adherence is a particular concern in older persons, with the 
prevalence of factors associated with poor adherence, such as mul-
timorbidity and greater regimen complexity, increasing with age.6–8
Multiple factors at the drug, patient, provider, and institutional 
levels may explain non- adherence in the specific population of 
older people, including: (a) increased vulnerability to drug- related 
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Abstract
Objective: Medication adherence is a major challenge in the treatment of older pa-
tients; however, they are under- represented in research. We undertook a systematic 
review focused on older patients to assess the reasons underlying non- adherence in 
this population.
Methods: We searched multiple electronic databases for studies reporting reasons 
for non- adherence to medication regimens in patients aged 75 years and over. Our 
results were not limited to specific diseases, health- care settings, or geographical 
locations. The quality of eligible studies was assessed using the Newcastle- Ottawa 
Scale. A narrative synthesis of findings was performed.
Results: A total of 25 publications were included, all of which were in community 
settings. Frequent medication review and knowledge regarding the purpose of the 
medication were positively associated with adherence. Factors associated with poor 
adherence were multimorbidity, cognitive impairment, complex regimens with multi-
ple prescribing physicians, and problems with drug storage or formulation.
Conclusion: These findings suggest that interventions to improve adherence could 
focus on medication review aimed at simplifying regimens and educating patients 
about their treatment. Groups with poor adherence that may benefit most from such 
a model include patients with multiple comorbidities and cognitive impairment.
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problems through pharmacodynamic and pharmacokinetic changes9; 
(b) high prevalence of comorbidity with subsequent polypharmacy 
and functional impairment10–12; (c) elevated risk of drug interactions 
with increasing medication burden13,14; and (d) high rates of service 
use across settings, leading to multiple providers and regimen com-
plexity.15 These problems rarely occur in isolation and can be both 
the cause and effect of non- adherence, leading to a cycle of escalat-
ing adversity. Despite this, studies that explicitly consider this older 
population appear to be under- represented, and those that do tend 
to focus on a single disease. We set out to quantify the factors po-
tentially associated with adherence by undertaking a systematic re-
view of studies addressing these issues specifically in persons aged 
≥75 years, enabling synthesis of results across different diseases and 
health- care settings.
2  | METHODS
2.1 | Search strategy and selection criteria
We used the following search terms in PubMed, adapting them for 
EMBASE and Web of Science: (Complia*/Non- complia*) (Adher*/
Non- adher*) (Concordan*/Non- concordan*) (Elder*/Old*/Geriatr*/
Aged/Senior). References for included articles and relevant litera-
ture reviews were also hand- searched for additional relevant publi-
cations. The search was completed in November 2017.
After screening title and abstract, the full text was reviewed. The 
majority of screening was carried out by A.S., with a sample inde-
pendently carried out by a second reviewer (R.R.) and cross- checked 
to ensure validity and reproducibility. Any uncertainty was resolved 
following discussion with a third reviewer (D.D.). Screening and full- 
text review was undertaken using Covidence.16
We used the following inclusion criteria:
• Population—Studies that only included participants aged 75 or 
over; studies in which the mean age of participants was ≥75 years; 
or studies that reported data separately for participants aged ≥75.
• Intervention—Both interventional and non-interventional studies 
were considered.
• Outcomes—Studies with an operational definition of adherence.
• Analysis—Studies quantifying associations between any mea-
sured factors and adherence.
We applied the following exclusion criteria: non- English pub-
lications; articles that had not undergone full peer review, such as 
conference abstracts/posters; publications relating solely to the 
cost of medicines or cost analysis; and studies published prior to 
2000 due to evolutions in prescribing practice over the last two 
decades.
2.2 | Data extraction
Data were extracted and entered into a custom template made by the 
first author. Data were extracted twice by two independent review-
ers (A.S. and M.W.C.). Any inconsistencies were resolved by a third re-
viewer (D.D.). Extracted data included basic information about the study 
(timing, design, location/setting, sample size, and demographics of the 
F IGURE  1 PRISMA flowchart 
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TABLE  1 Characteristics of included studies
Citation Study design Sample Setting Data collection Adherence assessments Covariates Summary findings Quality Comments
Barat et al 200118 Cross- sectional
Random sample from population 
register
Patients aged 75 prescribed 
medication by GP
Size = 348
Mean age = 75
M:F = 43:57
Denmark
Patients living in own homes
Structured interview with  
medical, cognitive and  
functional assessment
Drug score, 
dose score and regimen 
score calculated 









Number of prescribing 
physicians*
Number of drugs*
Number of OTC drugs
Use of compliance aids
Positive association: 
Not having dementia, 
Knowledge of purpose of 




Increasing number of prescribers, 
Increasing number of drugs
Random sample from population 
register Structured interview with 
verification from GP record
N- O score = 6
Borah et al 201019 Cohort
All eligible members of health plan 
included
All new initiators of Alzheimer’s 
disease medication
Size = 3091
Mean age = 80
M:F = 36:64
USA
Members of large health plan
Baseline information from  
electronic health record 
1- year follow- up of  
pharmacy fill data
MPR calculated for 
dementia medication











All eligible patients included from large 
register
Retrospective cohort therefore no 
dropouts
N- O score = 8
For every one under 
increase in pill burden, 
likelihood of adherence if 
increased by 19%. Did not 
control for caregiver 
support
Bourcier et al 201720 Cross- sectional
All eligible patients within 
geographical area invited
Patients aged > 75 with a GP 
prescription
Size = 1206
Mean age = 82
M:F = 35:65
France
Community pharmacy in Greater 
Paris
Structured interview and  
access to pharmacy record
Girerd score




Use of generic name*
Complete written regimen






Use of generic name
Reports “adjusted odds ratios” but does 
not state which variables were 
controlled for
N- O score = 3
Choudhry et al 200821 Cohort
All eligible members from health 
plan included
All patients discharged from hospital 
following first myocardial 
infarction
Size = 33 646
Mean age = 81
M:F = 25:75
USA
Members of large health plan
Medicare PACE and  
PAAD records
PDC calculated COPD*












Large retrospective cohort study Odds 
ratios adjusted for several important 
factors
N- O score = 8
Many diseases were 
assessed; COPD was the 




Cooper et al 200522 Cross- sectional
Participants of AdHOC study
Participants invited from a 
“representative area” judged by 
national lead
Size = 3881
Mean age = 82
M:F = 25:75
Europe (11 countries) Structured interview Self- reported adherence 






























Each sample judged to be representa-
tive of that country
Participants derived from other study 
so perhaps represent motivated 
individuals
N- O score = 6
Cohort identified from 
participants of the AdHOC 
study
Fallis et al 201323 Cohort
Consecutive discharges from 
hospital
All discharges who were prescribed 
a new medication
Size = 232
Mean age = 78
M:F = 49:51
Canada
Consecutive discharges from 
hospital followed into the 
community
Review of electronic pharmacy  
record and discharge summary




Discharge to long- term care*
Number of medications
Inclusion of primary care 
physician’s name on script
Negative association: 
Discharge to long- term care
Representative cohort
Data sourced from electronic health 
record
N- O score = 8
Foebel et al 201224 Cross- sectional
Patients assessed under RAI- HC
Patients with heart failure assessed 
for care needs





Review of RAI- HC validated  
against medical records
Medication use in past 
7 days Deemed 






Caregiver does not live with client
Very large sample size with multivariate 
regression
N- O score = 6
Highest impact on 
adherence if caregiver is 
stressed and does not live 
with client
Garcia- Sempere et al 
201725
Cohort
Patients discharged from hospital
Patients admitted with hip fracture 
and prescribed bone protection
Size = 4856
84% aged ≥ 75
M:F = 13:87
Spain
Cohort identified from hospital 
discharges followed into the 
community
Review of electronic  
health record
PDC for bone protection 
















Representative cohort of this 
population
4- year follow- up period
Attrition rate not stated
N- O score = 7
Only considered adherence 
to bone protection. As age 
increased, risk of 
non- adherence also 
increased.
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Citation Study design Sample Setting Data collection Adherence assessments Covariates Summary findings Quality Comments
Hayes et al 200926 Cross- sectional
Retirement village residents given 
additional vitamin C tablet
Recruited from 2 retirement villages
Size = 38




All residents invited from the 2 
villages
Electronic pill box measurement  
for additional tablet
Dose count and timing of 
dose measured
Non- adherent if < 80%
Cognitive function* Positive association: 
Higher cognitive function
Very small study
Only controlled for number of drugs
N- O score = 4
Effect of cognitive function 
persisted after adjustment 
for number of medications
Jerant et al 201127 Cohort
Pill count every 6 months
Sample derived from Ginkgo biloba 
trial
Size = 771






















Median follow- up 6.1 years Cohort 
predominantly well- educated white 
males
N- O score = 8
1 standard deviation in 
3MSE score increases 
non- adherence by 3%. 
5- year increment in age 
increased non- adherence 
by 1.3%.
Lee et al 201328 Cohort
Interviews via social work outreach 
team
Sample recruited via social workers
Size = 86




Structured interview with  
MMAS score














Small sample of specific group
Does not control for other variables
N- O score = 6
Defined polypharmacy as ≥ 
9 drugs
Li et al 200829 Cross- sectional
Questionnaire given to sample of 
Mandarin speakers
Convenience sample from Asian 
health clinic
Size = 144
Mean age = 75
M:F = 52:48
USA
Community based via Asian 
health clinic
Self- report questionnaire 
With MMAS score
Non- adherent if ≤80% Sex*




Length of time since immigration*
Positive association: 
Female sex
Longer time since immigration
Small sample of very specific group
Self- report with no verification
N- O score = 4
Beliefs regarding Western 
and Chinese medicine 
were not significant
Lindquist et al 201230 Cross- sectional
Interview following admission to 
hospital
Recruited from acute admissions 
ward
Size = 254




recruitment on acute 
admissions ward







Poor health literacy increases risk 
of unintentional non- adherence
Good health literacy increases risk 
of intentional non- adherence
Relies on self- report during interview
N- O score = 5
Mini- Mental State 
Examination cutoff for 
cognitive impairment 
determined by level of 
education
Mansur et al 200831 Cohort
Follow- up of discharges from 
hospital
Recruited from acute geriatric ward
Size = 198
Mean age = 81
M:F = 38:62
Israel
Follow- up acute geriatric 
admissions
Telephone interview ±  
verification with GP




No contact with GP
Polypharmacy
High number of regimen changes
Verification of self- report with GP
N- O score = 8
Polypharmacy defined as ≥7 
drug types
Marcum et al 201332 Cross- sectional
Questionnaire with subset of large 
population cohort.
Participants of Health, Ageing and 
Body Composition Study with 
HTN ± DM ± CHD
Size = 897























Hospitalization in previous 
6 months
Black race
Representative sample from large 
population cohort
Outcome assessed by self- report
N- O score = 4
All patients had at least one 
of DM/CHD/HTN. With 
reference to 1 of 3, 
2 of 3 worsened adherence 
and 3 of 3 improved 
adherence.




Patients taking NOAC in primary 
care
Size = 370
Mean age = 75
M:F = 47:53
Spain
Patients recruited via primary 
care and specialized researchers













1- year follow- up period
N- O score = 7
Definitions of current 
diseases, bodyweight and 
polypharmacy not given.
Moisan et al 200234 Cross- sectional
Interviews with patients recruited 
via ambulatory care
Cohort recruited via ambulatory 
care
Size = 325
Mean age = 78
M:F = 17:83
Canada
Community follow- up of patients 
recruited via ambulatory care














Belief drugs have little/no effect
Predominantly female sample
N- O score = 5
Reports only crude odds 
ratios
Ownby et al 200635 Cross- sectional
Interview with users of memory 
disorder clinic
Convenience sample from memory 
clinic
Size = 63
Mean age = 76
M:F = 29:71
USA
Recruited via memory clinic
Interview plus verification with  
carers and medical records








Total number of drugs
Positive association: 




Relies on self to remember doses
Side- effects
Adherence based on self- report with 
verification with carers
N- O score = 5
P- values given but no odds 
ratios
TABLE  1  (Continued)
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Citation Study design Sample Setting Data collection Adherence assessments Covariates Summary findings Quality Comments
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(Continues)
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participants), method of data collection, definition of adherence, and any 
measured associations (if any). Study quality was assessed by the same 
independent reviewers using the Newcastle- Ottawa Scale17 rating: se-
lection, comparability, and outcome (maximum score = 9 points).
3  | RESULTS
Of the 6346 publications identified, 540 were eligible for full- 
text review and 25 met the criteria for inclusion (Figure 1). The 
Citation Study design Sample Setting Data collection Adherence assessments Covariates Summary findings Quality Comments





Recruited via memory clinic
Interview with cognitive testing  
and electronic pill monitoring
Continuous scale based on 
electronic monitoring







N- O score = 7
Participants all have clinical 
diagnosis of memory 
problem and treated with 
cholinesterase inhibitor or 
memantine. 
Poor adherence predicted 
cognitive decline, but 
cognition did not predict 
adherence. Effect of 
caregiver presence 
attenuated over time
Pasina et al 201437 Cohort
Interview with patients recruited 
from acute medical ward and 
followed into the community
First 100 patients discharged from 
ward with polypharmacy
Size = 100
Mean age = 78
M:F = N/A
Italy
Recruited via acute medical unit 
and followed into the 
community
Structured interview Medication level: mean 
adherence of each patient
Patient level: % of patients 






Non- adherent had higher number 
of prescriptions than adherent 
(9.5 vs. 8.2, P = 0.043)
Length of study = 3 months
Does not control for other variables
Odds ratios not given
N- O score = 5
Piper et al 201738 Cross- sectional
Random sample of Medicare 
beneficiaries
5% sample of Medicare beneficiaries 
with epilepsy





Access to medical record PDC from electronic health 









Being eligible for low- income 
subsidy
Negative association: 
Comorbid conditions: 1- 3 = OR 
1.09, 4+ = OR 1.31
Seeing neurologist close to 
diagnosis
African American/Hispanic/Asian 




Random sample of largest US electronic 
health database Multivariate logistic 
regression
N- O score = 6
Large well- designed study 
specific to patients with 
epilepsy
Salter et al 201439 Cohort
Interviews in a subset of the MRC 
SCOOP trial over 18 months
Geographical subset selected from 
SCOOP trial
Size = 30




Structured interview Self- report during interview 







No factors had significant 
association
Very small sample
Only female participants Does not 
control for other variables
N- O score = 5
As such a small sample size, 
the study may be 
under- powered.
Sheer et al 201640 Cohort
Evaluation of pharmacy record of 
Medicare beneficiaries
Patients in receipt of Medicare 
prescription for an intra- ocular 
hypotensive agent
Size = 73 256




Access to electronic pharmacy  
record
PDC specifically for 
intra- ocular agents












Cohort identified retrospectively 
therefore no dropouts
Large cohort Multivariate logistic 
regression
N- O score = 8
Study specific to 
intra- ocular agents
Turner et al 200941 Cross- sectional
Interviews with patients identified 
in primary care
“Representative sample” from 
primary care record
Size = 202




Structured interview Non- adherent if any dose 






Checks blood pressure at home
Trouble following advice
Polypharmacy*
Runs out of medication*
Negative association: 
≥4 antihypertensive medications
Runs out of medication
Adjustment made for demographics, 
treatment regimen, and sampling 
weights
N- O score = 5
Primary focus of study was 
antihypertensive 
medications
Ulfvarson et al 200742 Cross- sectional
Hospital discharges followed into 
the community
All eligible admissions to the acute 
medical ward invited
Size = 200
Mean age = 79
M:F = 48:52
Sweden
Sample identified in hospital and 
assessed in the community
Interview with medical record  
linkage







Experience of side- effects
Polypharmacy
Use of OTC/herbal meds
Sufficient information
Sufficient time with doctor/nurse
Use of compliance aid
No factors had significant 
association
Multivariate logistic regression
N- O score = 6
Relatively small sample. 
Perhaps the study was 
under- powered
Abbreviations: 3MSE, modified Mini- Mental State Examination; ADLs, activities of daily living; BMI, body mass index; CHD, coronary heart disease; 
 COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; iADLs, instrumental activities of daily living; MCA,  
medication compliance aid; MMAS, Morisky Medication Adherence Scale; MPR, medication possession ratio; N- O score, Newcastle- Ottawa score;  
NOAC, novel oral anticoagulant; OTC, over- the- counter; PAAD, New Jersey Pharmaceutical Assistance for the Aged and Disabled; PACE,  
Pennsylvania Pharmaceutical Assistance Contract for the Elderly; PDC, proportion of days covered; RAI- HC, Resident Assessment  
Instrument – Home Care.
*Statistically significant association. 
TABLE  1  (Continued)
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majority of those eligible for inclusion were observational stud-
ies (one randomized controlled trial, 11 cohort, and 13 cross- 
sectional) based in Europe or North America. Participants were 
community dwelling (range n = 27 to n = 140 000), although 
some studies assessed specific groups within the community, 
such as those post- hospitalization or memory clinic users 
(Table 118–42). Operational definitions of non-adherence var-
ied, even when the method of data collection was the same. 
Citation Study design Sample Setting Data collection Adherence assessments Covariates Summary findings Quality Comments





Recruited via memory clinic
Interview with cognitive testing  
and electronic pill monitoring
Continuous scale based on 
electronic monitoring







N- O score = 7
Participants all have clinical 
diagnosis of memory 
problem and treated with 
cholinesterase inhibitor or 
memantine. 
Poor adherence predicted 
cognitive decline, but 
cognition did not predict 
adherence. Effect of 
caregiver presence 
attenuated over time
Pasina et al 201437 Cohort
Interview with patients recruited 
from acute medical ward and 
followed into the community
First 100 patients discharged from 
ward with polypharmacy
Size = 100
Mean age = 78
M:F = N/A
Italy
Recruited via acute medical unit 
and followed into the 
community
Structured interview Medication level: mean 
adherence of each patient
Patient level: % of patients 






Non- adherent had higher number 
of prescriptions than adherent 
(9.5 vs. 8.2, P = 0.043)
Length of study = 3 months
Does not control for other variables
Odds ratios not given
N- O score = 5
Piper et al 201738 Cross- sectional
Random sample of Medicare 
beneficiaries
5% sample of Medicare beneficiaries 
with epilepsy





Access to medical record PDC from electronic health 









Being eligible for low- income 
subsidy
Negative association: 
Comorbid conditions: 1- 3 = OR 
1.09, 4+ = OR 1.31
Seeing neurologist close to 
diagnosis
African American/Hispanic/Asian 




Random sample of largest US electronic 
health database Multivariate logistic 
regression
N- O score = 6
Large well- designed study 
specific to patients with 
epilepsy
Salter et al 201439 Cohort
Interviews in a subset of the MRC 
SCOOP trial over 18 months
Geographical subset selected from 
SCOOP trial
Size = 30




Structured interview Self- report during interview 







No factors had significant 
association
Very small sample
Only female participants Does not 
control for other variables
N- O score = 5
As such a small sample size, 
the study may be 
under- powered.
Sheer et al 201640 Cohort
Evaluation of pharmacy record of 
Medicare beneficiaries
Patients in receipt of Medicare 
prescription for an intra- ocular 
hypotensive agent
Size = 73 256




Access to electronic pharmacy  
record
PDC specifically for 
intra- ocular agents












Cohort identified retrospectively 
therefore no dropouts
Large cohort Multivariate logistic 
regression
N- O score = 8
Study specific to 
intra- ocular agents
Turner et al 200941 Cross- sectional
Interviews with patients identified 
in primary care
“Representative sample” from 
primary care record
Size = 202




Structured interview Non- adherent if any dose 






Checks blood pressure at home
Trouble following advice
Polypharmacy*
Runs out of medication*
Negative association: 
≥4 antihypertensive medications
Runs out of medication
Adjustment made for demographics, 
treatment regimen, and sampling 
weights
N- O score = 5
Primary focus of study was 
antihypertensive 
medications
Ulfvarson et al 200742 Cross- sectional
Hospital discharges followed into 
the community
All eligible admissions to the acute 
medical ward invited
Size = 200
Mean age = 79
M:F = 48:52
Sweden
Sample identified in hospital and 
assessed in the community
Interview with medical record  
linkage







Experience of side- effects
Polypharmacy
Use of OTC/herbal meds
Sufficient information
Sufficient time with doctor/nurse
Use of compliance aid
No factors had significant 
association
Multivariate logistic regression
N- O score = 6
Relatively small sample. 
Perhaps the study was 
under- powered
Abbreviations: 3MSE, modified Mini- Mental State Examination; ADLs, activities of daily living; BMI, body mass index; CHD, coronary heart disease; 
 COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; iADLs, instrumental activities of daily living; MCA,  
medication compliance aid; MMAS, Morisky Medication Adherence Scale; MPR, medication possession ratio; N- O score, Newcastle- Ottawa score;  
NOAC, novel oral anticoagulant; OTC, over- the- counter; PAAD, New Jersey Pharmaceutical Assistance for the Aged and Disabled; PACE,  
Pennsylvania Pharmaceutical Assistance Contract for the Elderly; PDC, proportion of days covered; RAI- HC, Resident Assessment  
Instrument – Home Care.
*Statistically significant association. 
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Methods for ascertaining adherence included: (a) data collected 
from electronic monitoring systems; (b) information from medi-
cal records, such as prescription fill data and insurance claims; 
and (c) data from interviews or self- report questionnaires. 
These differences were considered when drawing broader 
conclusions.
F IGURE  2 Effect of older age on 
adherence. Forest plot showing the 
association of age on adherence in 
selected studies reporting comparable 
age relationships. No pooled estimate is 
shown due to substantial heterogeneity 
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F IGURE  3 Effect of multimorbidity 
on adherence. Forest plot showing 
the association of multimorbidity on 
adherence in selected studies reporting 
comparable multimorbidity measures. 
No pooled estimate is shown due to 
substantial heterogeneity across studies. 
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F IGURE  4 Effect of cognitive 
impairment on adherence. Forest plot 
showing the association of cognitive 
impairment on adherence in selected 
studies reporting comparable measures of 
cognitive impairment. No pooled estimate 
is shown due to substantial heterogeneity 
across studies. CI, confidence interval; ES, 
effect size
Study
Lindquist et al 201230
Cooper et al 200522
Barat et al 200118
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3.1 | Patient factors
Factors positively associated with adherence included being of 
European descent,21,32,38 and having high health literacy and infor-
mation about the treatment purpose and consequences of omis-
sion.18,30 With regard to specific diseases, only cancer was shown to 
have a positive association with adherence.32
Demographic factors negatively associated with adherence in-
cluded older age19,25,27,35,38 and being male,21,25,28,29,40 although 
these associations were weak (Figure 2). Health behaviors nega-
tively associated with adherence were excessive alcohol consump-
tion.22 Other factors negatively associated with adherence included 
the neurotic personality trait (other personality traits did not have 
a significant impact),27 recent hospitalization, and lack of contact 
with a general practitioner.31,32 Higher levels of comorbidity were 
also associated with poorer adherence (Figure 3).9,25,33,38 Compared 
with people who did not have these diseases, stroke,25 falls,32 sleep 
disturbance,32 and chronic obstructive pulmonary disease21 were all 
found to have an independent negative effect on adherence due to 
their presence. There was a suggestion that cognitive impairment 
shares a negative association with adherence18,22,26,27 (Figure 4), al-
though these results contrasted findings from two smaller studies. 
Both of these studies not demonstrating any association featured 
small sample sizes, one of which recruited patients from a memory 
clinic (i.e., without a healthy control comparator).30,35
General education did not appear to be associated with adher-
ence,18,27,32,35,42 and nor were psychiatric diagnoses.18,22,41 The two stud-
ies reporting body mass index associations had discordant results.27,33
3.2 | Medication factors
The only medication factor positively associated with adherence 
was having had a medication review in the last 6 months, although 
this was only assessed in one study.22 Factors negatively associated 
with adherence included recently changed medication regimens31 
and those regimens that had been formulated through involvement 
of greater numbers of prescribing physicians.18 Patient dissatisfac-
tion with the drug formulation and difficulties with drug storage, 
such as accumulation of drugs and scattered drug storage, were also 
negatively associated with adherence.20,28,41
In general, adherence was negatively associated with larger num-
bers of prescribed drugs, but this was not consistent. Where reports 
defined polypharmacy with a higher cutoff (such as greater than 
seven or even nine drugs), polypharmacy was more likely to have a 
negative association with adherence.28,31,37 The studies that used a 
continuous scale of overall pill burden were less likely to find an as-
sociation between polypharmacy and adherence.21,22,35 One study 
reported improved adherence with increasing pill burden.19
Compliance aids were not consistently associated with adher-
ence (Figure 5).18,20,34,42 One study found that compliance aids were 
associated with medications being taken on a given day but not im-
proved adherence to the correct dosage or regimen.18
3.3 | Institutional factors
Six studies reported on the presence of a caregiver, five of which 
found no association with adherence.22,27,29,34,37 One study found 
that a resident caregiver improved adherence focused on patients 
with mild cognitive impairment.34 There was no consensus be-
tween studies that reported the setting in which the patient lived, 
and similarly whether the patient lived alone or with someone 
else.18,20–23,34
4  | DISCUSSION
Factors most consistently negatively associated with adherence in 
this older population were related to complex regimens with mul-
tiple prescribing physicians, and problems with medication storage 
and formulation. Multimorbidity and cognitive impairment were also 
negatively associated with adherence. In contrast, recent medication 
review and knowledge about the purpose of the treatment and con-
sequences of omission were positively associated with adherence. 
However, the use of medication compliance aids and, in the absence 
of cognitive impairment, the presence of a caregiver did not appear 
to be associated with adherence. Although we sought to examine this 
question specifically in older populations, we found only a weak neg-
ative association with adherence at these ages. Taken together, our 
findings suggest that interventions for improving adherence should 
be aimed at patients with multimorbidity and cognitive impairment, 
F IGURE  5 Effect of compliance 
aids on adherence. Forest plot showing 
the association of age on adherence in 
selected studies reporting comparable 
measures of use of compliance aids. 
No pooled estimate is shown due to 
substantial heterogeneity across studies. 
CI, confidence interval; ES, effect size
Barat et al 200118 
Moisan et al 200234 








264  |     SMAJE Et Al.
with the goal of improving knowledge about the treatment and sim-
plifying regimens.
This review goes beyond the findings of an earlier systematic re-
view by considering studies conducted outside of the USA and focus-
ing solely on patients aged over 75 years.43 Previous work found it 
difficult to draw broad conclusions due to differences in the definition 
and measurement of adherence and the limited number of publications 
that were included. Our findings support the conclusions that health- 
related knowledge, cognitive impairment, and polypharmacy have an 
impact on adherence. However, our analysis adds uncertainty to the 
notion that medication compliance aids are effective. This suggests 
that future investigations into other forms of adherence support are 
merited. The utility of compliance aids has been debated in a recent 
European Medicines Agency Reflection Paper, in which problems re-
lating to the recognition of medicines due to removal from their origi-
nal packaging were specifically highlighted.44 We found that external 
reminders (such as caregivers and phone call reminders) were more 
effective in older adults with cognitive impairment.45
Our results should be treated with caution. As with previous 
research in this area,43 the primary limitation relates to the quan-
tity of available research. Though we used broad inclusion crite-
ria, we only identified 25 eligible publications. Most of these were 
observational, with very few randomized controlled trials having 
been undertaken. A further limitation concerns the lack of a clear 
consensus definition of adherence and polypharmacy. As such, stud-
ies relating to the administration of medications are heterogenous, 
both in the populations studied and in their outcome definition. 
Nonetheless, the strongest associations hold despite these opera-
tional differences. The major strengths of our approach have been 
our specific focus on older populations, a previously unexplored 
group with a high prevalence of adherence issues, and inclusion 
of studies across a range of English- language health- care systems.
The mechanisms underlying factors with an impact on adherence 
are strongly interlinked. An individual with multiple medical prob-
lems is likely to see several health- care practitioners, all of whom 
may make changes to their regimen. This is likely to be confusing, 
thereby leading to poor adherence. Cognitive impairment across 
domains such as episodic memory and executive function will have 
consequences that include both intentional and unintentional non- 
adherence. The prevalence of multimorbidity and cognitive impair-
ment increases with age, and appears to become more important 
for adherence than age per se. As such, medication review with the 
opportunity to clarify and simplify prescription regimens and for the 
patient to ask questions might be most effective in this group. This is 
consistent with having fewer prescribing physicians and knowledge 
about the treatment being positively associated with adherence, and 
should be considered in light of our finding that neither the presence 
of a carer (in the absence of cognitive impairment) nor compliance 
aids showed any association with adherence. A recent case report 
discussed the potential utility of knowing a patient’s medication 
schedule so that the pill burden is not unnecessarily increased when 
changes need to be made, something that could be achieved with 
this single- point- of- care model.46 Ultimately, it may be that the most 
effective interventions focus on patient empowerment rather than 
the influence of external factors, even if individuals are living with 
cognitive impairment or dementia.47
Overall, this review supports our understanding that non- 
adherence is prevalent amongst older patients and is multifactorial 
in origin. We suggest that interventions to improve adherence in this 
population might be most effective if delivered in the form of a med-
ication review, with the aim of simplifying prescription regimens and 
providing patient education on the indications of individual thera-
pies. If provided from a single point of care, this would reduce the 
number of prescribing physicians and monitor the frequency of regi-
men changes. In addition, switching formulation to that preferred by 
the patient and screening for drug storage problems could also be 
effective in optimizing adherence. In particular, it would seem that 
specific targeting of those with cognitive impairment and multimor-
bidity would address an at- risk group with unmet needs.
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